Myeloid cell TBK1 restricts inflammatory responses
Proinflammatory cytokine production by innate immune cells plays a crucial role in inflammatory diseases, but the molecular mechanisms controlling the inflammatory responses are poorly understood. Here, we show that TANK-binding kinase 1 (TBK1) serves as a vital regulator of proinflammatory macropha...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 119; no. 4; pp. 1 - 11 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
25.01.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Proinflammatory cytokine production by innate immune cells plays a crucial role in inflammatory diseases, but the molecular mechanisms controlling the inflammatory responses are poorly understood. Here, we show that TANK-binding kinase 1 (TBK1) serves as a vital regulator of proinflammatory macrophage function and protects against tissue inflammation. Myeloid cell–conditional Tbk1 knockout (MKO) mice spontaneously developed adipose hypertrophy and metabolic disorders at old ages, associated with increased adipose tissue M1 macrophage infiltration and proinflammatory cytokine expression. When fed with a high-fat diet, the Tbk1-MKO mice also displayed exacerbated hepatic inflammation and insulin resistance, developing symptoms of nonalcoholic steatohepatitis. Furthermore, myeloid cell–specific TBK1 ablation exacerbates inflammation in experimental colitis. Mechanistically, TBK1 functions in macrophages to suppress the NF-κB and MAP kinase signaling pathways and thus attenuate induction of proinflammatory cytokines, particularly IL-1β. Ablation of IL-1 receptor 1 (IL-1R1) eliminates the inflammatory symptoms of Tbk1-MKO mice. These results establish TBK1 as a pivotal anti-inflammatory mediator that restricts inflammation in different disease models. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 2T.G., T.L., and C.-J.K. contributed equally to this work. Author contributions: T.G., T.L., C.-J.K., D.J., and L. Zhang designed research; T.G., T.L., C.-J.K., L. Zhang, D.J., X.X., L. Zhu, Y.L., and X.C. performed research; T.G., T.L., and C.-J.K. analyzed data; and T.G., C.-J.K., and S.-C.S. wrote the paper. 1Present address: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 510060. 6Present address: Research and Development, Ziopharm Oncology, Inc., Boston, MA 02129. 3Present address: Department of Laboratory Medicine, West China Second University Hospital, State Key Laboratory of Biotherapy and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China 610041. Edited by Katherine Fitzgerald, University of Massachusetts Medical School, Worcester, MA; received April 27, 2021; accepted November 23, 2021 5Present address: Center for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China 450052. 7Present address: Pharmacology Division, AbbVie, South San Francisco, CA 94080. |
ISSN: | 0027-8424 1091-6490 1091-6490 |
DOI: | 10.1073/pnas.2107742119 |